Mark Iwicki
About Mark Iwicki
Mark Iwicki is a seasoned executive in the pharmaceutical industry, currently serving as Chairman and CEO of Kala Pharmaceuticals and holding various board positions at multiple companies. He has extensive experience in leadership roles, including Vice President at Novartis Pharmaceuticals and Chief Commercial Officer at Sepracor.
Current Role at Nimbus
Mark Iwicki has held the position of Director at Nimbus Therapeutics since 2015. His tenure at Nimbus spans over nine years, during which he has contributed to the company's strategic direction and development initiatives. Nimbus Therapeutics focuses on advancing drug discovery and development through innovative approaches, and Iwicki's leadership plays a crucial role in guiding the organization.
Leadership Experience at Novartis Pharmaceuticals
Iwicki served as Vice President and head of the Cardiovascular Business Unit at Novartis Pharmaceuticals. In this role, he provided leadership across multiple therapeutic areas, including Arthritis, Osteoporosis, Gastrointestinal, Hormone Replacement Therapy, Infectious Disease, and Urology. His experience at Novartis is marked by a focus on product development and market strategy.
Educational Background
Mark Iwicki studied at Loyola University Maryland, where he earned a Master of Business Administration (MBA) with a focus on Marketing and Finance from 1990 to 1992. Prior to that, he attended Ball State University, achieving a Bachelor of Science (B.S.) in Business Administration and Management from 1985 to 1989. His educational background has provided a strong foundation for his career in the pharmaceutical and biotechnology sectors.
Career Progression and Previous Roles
Iwicki began his career in management positions at Astra Merck and Merck. He later served as Chief Commercial Officer at Sepracor, where he oversaw six marketed products and a late-stage development portfolio. Additionally, he held director roles at Pulmatrix Inc. and Aimmune Therapeutics from 2015 to 2020. His diverse experience across various companies has equipped him with extensive knowledge in the pharmaceutical industry.
Board Leadership and Other Affiliations
In addition to his role at Nimbus Therapeutics, Iwicki serves as Board Chair at Aerovate Therapeutics, Inc. since 2021, and at Akero Therapeutics since 2018. He also holds the position of Board Chair at Third Harmonic Bio since 2020 and serves on the Board of Directors for Taris Biomedical. His involvement in these organizations reflects his commitment to advancing healthcare innovation.